Investigating the mechanisms of drug sensitivity and resistance to targeted therapies for lung cancer.

Main Header
Go to Research

Featured Publication

LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers

Published May 2, 2025
See all Publications
...
Aaron Hata, MD PhD, Principal Investigator

Mission

Our mission is to advance the development of new therapies for patients with lung cancer through scientific discovery of the molecular mechanisms of drug sensitivity and resistance, understanding tumor evolution during treatment, and identification of targetable vulnerabilities to guide investigation of novel therapeutic strategies.

We are a diverse group of physicians & scientists with expertise in cell biology, pharmacology, genetics, immunology and computational biology. We are currently recruiting at all levels - if you would like to join our team, please contact us.

Meet the Team

News — December 14, 2024

IASLC

Aaron speaks at the 2024 Hot Topic in Basic & Translational Science: Tolerance and Resistance to Targeted Therapy in NSCLC conference sponsored by IASLC.

Go to News

News — December 5, 2024

BTC

The Hata Lab will be a part of the new PoweRD 2 Cure ALK+ Lung Cancer TeamLab announced by Breakthrough Cancer. We will focus on understanding and eliminating residual disease…

Go to News

We are looking for people to partner with us in our mission to improve treatments for patients with lung cancer.

Join Us Support Us